BioNTech SE (BNTX) Cash from Discontinued Operations (2019 - 2025)
BioNTech SE (BNTX) posted Cash from Discontinued Operations of 912681309.82 for Q3 2025, up 450.36% sequentially from 165832094.29 in Q2 2025, and up 230.08% YoY from 276506427.74 in Q3 2024.
BioNTech SE (BNTX) Cash from Discontinued Operations (2019 - 2025) Analysis & Trends
BioNTech SE has reported Cash from Discontinued Operations for 7 years, with the latest figure at 912681309.82 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 912.68 Mn |
| Sep 30, 2025 | 912.68 Mn |
| Jun 30, 2025 | 165.83 Mn |
| Jun 30, 2025 | 165.83 Mn |
| Mar 31, 2025 | -821.21 Mn |
| Mar 31, 2025 | -821.21 Mn |
| Sep 30, 2024 | -701.65 Mn |
| Sep 30, 2024 | -701.65 Mn |
| Jun 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 1.75 Bn |
| Mar 31, 2024 | -344.70 Mn |
| Mar 31, 2024 | -344.70 Mn |
| Sep 30, 2023 | 883.06 Mn |
| Sep 30, 2023 | 883.06 Mn |
| Jun 30, 2023 | 4.78 Bn |
| Jun 30, 2023 | 4.78 Bn |
| Mar 31, 2023 | -727.08 Mn |
| Mar 31, 2023 | -727.08 Mn |
| Sep 30, 2022 | 4.82 Bn |
| Sep 30, 2022 | 4.82 Bn |